AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
BMO maintains AbbVie stock Outperform rating
BMO Capital Markets sustained its positive outlook on AbbVie Inc . (NYSE:ABBV) shares, maintaining an Outperform rating and a $208.00 price target. The firm's analyst, Evan David Seigerman, emphasized ...
centerforbiosimilars21h
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...
Teva price target raised to $30 from $23 at Piper Sandler
Piper Sandler raised the firm’s price target on Teva (TEVA) to $30 from $23 and keeps an Overweight rating on the shares after meeting with ...
Managed Healthcare Executive23h
Updated: UnitedHealth Group's 2024 Revenue Grows to Reach $400.3 Billion
In 2024, UnitedHealth Group saw full year revenue grow 8% over 2023 to reach $400.3 billion. Adjusted earnings from ...